US imaging company announces new breast cancer detection service

Delaware Imaging Network has announced the start of its new breast cancer detection service.

The network, a division of the diagnostic imaging company RadNet, will begin the implementation of its Enhanced Breast Cancer Detection (EBCD) in concert with a patient’s annual breast screening regimen.

For an additional fee, patients will be able to receive a screening mammography offering including the application of Saige-Dx™, an FDA-cleared AI technology, an AI-driven review applied to certain suspicious exams and findings, a lifetime risk assessment for breast cancer and a dedicated support line.

The company says EBCD presents a “significantly improved level of accuracy” in breast cancer detection, empowering women to take greater control of their health.

“AI is dramatically improving our detection capability and overall quality,” said Dr Howard Berger, president and CEO of RadNet.

Jacqueline Holt, director of breast imaging at Delaware Imaging Network, added:  “In medicine, the ability to see and detect disease with more certainty is a game-changer, driving better patient outcomes.

“We are using AI to detect breast cancers that the human eye might not notice. In my experience, the addition of these proven, FDA-cleared algorithms has allowed us to detect hundreds of cancers that otherwise would not have been found at the time of screening.”

In the past, many breast screening mammography patients have described a desire for more information about the reports and follow-ups they receive after their annual mammogram, including their lifetime risk of developing breast cancer.

While a breast density score, currently required in 38 states, is one factor in a patient’s lifetime risk for breast cancer, multiple factors can increase risk.

The EBCD service aims to offer a solution that addresses questions about breast cancer risk by providing reports and specialist support. Depending on the patient’s risk level, their referring physician might recommend a customised screening protocol.

The developers say EBCD is the first solution of its kind. According to Dr Berger, the service is an exciting and important endeavour the company has pursued.

“It serves as another example of how RadNet continues to lead radiology forward,” he added.